Clear Harbor Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Clear Harbor Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$130K	Hold	27,000	–	–	0.01%	431
2026 Q1	$122K	Sell	27,000 -47,761	-64%	-$209K	0.01%	430
2025 Q4	$360K	Hold	74,761	–	–	0.02%	340
2025 Q3	$339K	Sell	74,761 -5,000	-6%	-$18.4K	0.02%	339
2025 Q2	$246K	Hold	79,761	–	–	0.02%	361
2025 Q1	$278K	Hold	79,761	–	–	0.02%	333
2024 Q4	$261K	Buy	79,761 +5,000	+7%	+$18.4K	0.02%	328
2024 Q3	$288K	Sell	74,761 -26,000	-26%	-$99.7K	0.02%	300
2024 Q2	$311K	Sell	100,761 -15,500	-13%	-$46.5K	0.03%	287
2024 Q1	$300K	Sell	116,261 -23,000	-17%	-$59.6K	0.03%	289
2023 Q4	$348K	Buy	139,261 +7,500	+6%	+$14.7K	0.03%	267
2023 Q3	$267K	Buy	131,761 +78,761	+149%	+$165K	0.03%	280
2023 Q2	$122K	Hold	53,000	–	–	0.01%	331
2023 Q1	$161K	Hold	53,000	–	–	0.02%	348
2022 Q4	$123K	Buy	+53,000	New	+$127K	0.02%	337

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Clear Harbor Asset Management's ABUS Position: Q2 2026 in Review

Clear Harbor Asset Management held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 27,000 shares worth $130K. The position accounts for 0.01% of the portfolio, ranked #431.

Clear Harbor Asset Management first reported a position in ABUS in Q4 2022 and has held it in 15 quarters since. The position peaked at $360K in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Clear Harbor Asset Management held 27,000 shares of Arbutus Biopharma worth $130K as of Q2 2026.
Clear Harbor Asset Management left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up 0.01% of Clear Harbor Asset Management's portfolio in Q2 2026, its #431 holding.
Clear Harbor Asset Management first reported a position in Arbutus Biopharma in Q4 2022 and has held it in 15 quarters since.
Clear Harbor Asset Management's Arbutus Biopharma position peaked at $360K in Q4 2025.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Clear Harbor Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.